Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$11.42 USD

11.42
1,279,820

-0.34 (-2.89%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $11.42 0.00 (0.00%) 6:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.

Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally

Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.

Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View

Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.

Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales

Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.

bluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales

bluebird bio (BLUE) reports better-than-expected results in the third quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates

Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.

Is Dynavax Technologies (DVAX) Outperforming Other Medical Stocks This Year?

Here is how Dynavax Technologies (DVAX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus

Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.

Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated

Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth.

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. The company raises its guidance for full-year 2023 Caplyta sales.

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.

Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates

Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.

Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up

Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.

Moderna (MRNA) Beats on Q3 Earnings & Sales, Expects Lower COVID Demand

Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.

Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat

Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.

BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut

BioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company lowered its 2023 guidance due to global pricing and reimbursement delays for Roctavian.

Zoetis' (ZTS) Q3 Earnings Beat, Revenues Miss by a Whisker

Zoetis' (ZTS) third-quarter 2023 earnings surpass estimates. However, revenues fall marginally short. The strong performance of the companion animal portfolio drives year-over-year revenues.

Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View

Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023.

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.

Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up

Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.

Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up

Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.

Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates

Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.

Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat

Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.